Literature DB >> 731302

Lymphocytic infiltrates in primary glioblastomas and recidivous gliomas. Incidence, fate, and relevance to prognosis in 228 operated cases.

L Palma, N Di Lorenzo, B Guidetti.   

Abstract

The correlation existing in several human malignancies between lymphocytic infiltration and prolonged survival prompted this study. Two hundred selected patients who were operated on for glioblastoma were reviewed to investigate the incidence of the lymphocytic infiltration in the histological slides and its possible relevance to a better clinical course. The group that exhibited a definite lymphocytic infiltration (Group A, 11.5%) had a significantly longer preoperative history and postoperative survival (p less than 0.01) than the other two groups that presented slight or no infiltration (Group B, 23%, and Group C, 65%, respectively). In addition, biopsies of 28 recidivous gliomas were reviewed to study the fate of this lymphocytic infiltration in relation to time and therapy, such as irradiation and steroids which are known to depress the immune response. The authors found that severe lymphocytic infiltration is a rare immunobiological reaction which significantly improves the prognosis of a malignant brain tumor and seems not to be influenced by time, local x-ray therapy, or steroids.

Entities:  

Mesh:

Year:  1978        PMID: 731302     DOI: 10.3171/jns.1978.49.6.0854

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  59 in total

1.  CD8+ T-cell infiltrate in newly diagnosed glioblastoma is associated with long-term survival.

Authors:  Isaac Yang; Tarik Tihan; Seunggu J Han; Margaret R Wrensch; John Wiencke; Michael E Sughrue; Andrew T Parsa
Journal:  J Clin Neurosci       Date:  2010-08-19       Impact factor: 1.961

Review 2.  PD-1 Inhibitors: Do they have a Future in the Treatment of Glioblastoma?

Authors:  Mustafa Khasraw; David A Reardon; Michael Weller; John H Sampson
Journal:  Clin Cancer Res       Date:  2020-06-11       Impact factor: 12.531

3.  Ex vivo expansion of tumor-draining lymph node cells using compounds which activate intracellular signal transduction. I. Characterization and in vivo anti-tumor activity of glioma-sensitized lymphocytes.

Authors:  N G Baldwin; C D Rice; T M Tuttle; H D Bear; J I Hirsch; R E Merchant
Journal:  J Neurooncol       Date:  1997-03       Impact factor: 4.130

Review 4.  Immunotherapy for malignant glioma using human recombinant interleukin-2 and activated autologous lymphocytes. A review of pre-clinical and clinical investigations.

Authors:  R E Merchant; M D Ellison; H F Young
Journal:  J Neurooncol       Date:  1990-04       Impact factor: 4.130

5.  Increased immune gene expression and immune cell infiltration in high-grade astrocytoma distinguish long-term from short-term survivors.

Authors:  Andrew M Donson; Diane K Birks; Stephanie A Schittone; Bette K Kleinschmidt-DeMasters; Derrick Y Sun; Molly F Hemenway; Michael H Handler; Allen E Waziri; Michael Wang; Nicholas K Foreman
Journal:  J Immunol       Date:  2012-07-16       Impact factor: 5.422

6.  Craniocerebral epidermoids and dermoids. A review of 44 cases.

Authors:  G Rubin; R Scienza; A Pasqualin; L Rosta; R Da Pian
Journal:  Acta Neurochir (Wien)       Date:  1989       Impact factor: 2.216

7.  The mononuclear cell infiltrate compared with survival in high-grade astrocytomas.

Authors:  M L Rossi; N R Jones; E Candy; J A Nicoll; J S Compton; J T Hughes; M M Esiri; T H Moss; F F Cruz-Sanchez; H B Coakham
Journal:  Acta Neuropathol       Date:  1989       Impact factor: 17.088

8.  Absolute quantification of tumor-infiltrating immune cells in high-grade glioma identifies prognostic and radiomics values.

Authors:  A Reum Kim; Kyu Sung Choi; Min-Sung Kim; Kyung-Min Kim; Ho Kang; Sojin Kim; Tamrin Chowdhury; Hyeon Jong Yu; Chae Eun Lee; Joo Ho Lee; Soon-Tae Lee; Jae Kyung Won; Jin Wook Kim; Yong-Hwy Kim; Tae Min Kim; Sung-Hye Park; Seung Hong Choi; Eui-Cheol Shin; Chul-Kee Park
Journal:  Cancer Immunol Immunother       Date:  2021-01-08       Impact factor: 6.968

9.  A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.

Authors:  Donald M O'Rourke; MacLean P Nasrallah; Arati Desai; Jan J Melenhorst; Keith Mansfield; Jennifer J D Morrissette; Maria Martinez-Lage; Steven Brem; Eileen Maloney; Angela Shen; Randi Isaacs; Suyash Mohan; Gabriela Plesa; Simon F Lacey; Jean-Marc Navenot; Zhaohui Zheng; Bruce L Levine; Hideho Okada; Carl H June; Jennifer L Brogdon; Marcela V Maus
Journal:  Sci Transl Med       Date:  2017-07-19       Impact factor: 17.956

10.  Treatment of recurrent malignant glioma by repeated intracerebral injections of human recombinant interleukin-2 alone or in combination with systemic interferon-alpha. Results of a phase I clinical trial.

Authors:  R E Merchant; D W McVicar; L H Merchant; H F Young
Journal:  J Neurooncol       Date:  1992-01       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.